Results 151 to 160 of about 253,402 (288)

Cannabidiol in Anorexia Nervosa: A Double‐Blind Randomized Placebo Controlled Pilot Study to Test Safety, Pharmacokinetics, and Symptom Change

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Anorexia nervosa (AN) is a severe psychiatric disorder marked by an intense fear of gaining weight and persistent body dissatisfaction, both during periods of underweight and after weight restoration. The endocannabinoid system may offer therapeutic benefits, particularly in reducing anxiety.
Neha Sahota   +8 more
wiley   +1 more source

Antidepressant Pharmacogenetics [PDF]

open access: yesAmerican Journal of Psychiatry, 2017
Ajeet B, Singh, Chad A, Bousman
openaire   +2 more sources

Latent Trajectories of Body Mass Index and Depressive Symptoms in Inpatients With Anorexia Nervosa: Predictors and Outcomes

open access: yesInternational Journal of Eating Disorders, EarlyView.
ABSTRACT Objective Inpatient treatment aimed at weight restoration and psychiatric stabilization is often required for individuals with anorexia nervosa (AN). This study aimed to identify distinct trajectories of change in body mass index (BMI) and depressive symptoms during inpatient treatment, examine clinical predictors and outcomes, and test ...
Matteo Martini   +5 more
wiley   +1 more source

Sex‐specific elevated incidence of glaucoma associated with topiramate versus valproate or lamotrigine in epilepsy, not migraine: A population‐based cohort study

open access: yesEpilepsia, EarlyView.
Abstract Objective Topiramate has been linked to increased glaucoma risk, potentially through mechanisms involving ocular fluid shifts. However, comparative risks vs other antiseizure medications (ASMs) and variation by sex or indication remain uncertain.
Cuiling Wei   +10 more
wiley   +1 more source

Asiaticoside Attenuates Chronic Restraint Stress-Induced Hippocampal CA1 Neuronal Ferroptosis via Activating BDNF/Nrf2/GPX4 Signaling Pathway

open access: yesDrug Design, Development and Therapy
An Zhou,1– 3 Hao-Yinghua Feng,4 Chu-Ning Fan,3 Jun Wang,3 Zhong-Yu Yuan,3 Guang-Hui Xu,5 Cheng-Fu Li,6 Wei-Feng Huang,1 Li-Tao Yi3,7,8 1Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Xiamen University, School of Medicine,
Zhou A   +8 more
doaj  

Patterns of seizure frequency reduction in clinical trial participants with lower baseline seizure frequency

open access: yesEpilepsia, EarlyView.
Abstract Objective Inclusion and exclusion criteria of clinical trials for seizures aim to select representative participants with a high enough seizure frequency to evaluate the efficacy of treatment in a relatively short double‐blind period. To inform the selection of seizure frequency‐based inclusion criteria, we evaluated the association between ...
Wesley T. Kerr   +5 more
wiley   +1 more source

Individual Cognitive Remediation Therapy and Individual Emotion Skills Training for Anorexia Nervosa: A Case Series Study in a Paediatric Ward

open access: yesEuropean Eating Disorders Review, EarlyView.
ABSTRACT Introduction Adolescents with anorexia nervosa (AN) often present cognitive rigidity, impaired decision‐making, and difficulties processing emotions, all of which can impede engagement in treatment. The marked rise in paediatric hospitalisations for AN during the COVID‐19 pandemic highlights the urgent need for brief, targeted interventions in
Dario Marin   +4 more
wiley   +1 more source

An Investigation of Key Symptoms That Account for the Early Response Effect During Psychological Therapy for Eating Disorders

open access: yesEuropean Eating Disorders Review, EarlyView.
ABSTRACT Objective The early response effect, defined as a reliable symptomatic improvement during the initial phase of treatment, is the most robust predictor of recovery following eating disorder treatment. This study aimed to investigate which symptom domains mostly influence the early response effect. Methods Data from N = 232 adult patients (90.8%
Ammara Imtiaz   +3 more
wiley   +1 more source

Luzhou‐Flavor Baijiu Alleviates Stress‐Related Depressive‐Like Changes by NMDAR‐NO‐sGC‐cGMP Pathway

open access: yesFood Safety and Health, EarlyView.
Luzhou‐flavor baijiu (LFB) alleviates depressive‐like phenotypes in CRS‐induced mice and protects HT22 cells from corticosterone damage, with mechanisms linked to suppressing the NMDAR‐nNOS/iNOS‐NO‐sGC‐cGMP pathway. ABSTRACT Moderate alcohol consumption has been suggested to alleviate anxiety and depression; however, it remains unclear whether Luzhou ...
Li Xiong   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy